Enabling Next-Generation Biomanufacturing Using Cell-Free Technology

In recent years, new therapeutic formats with increasing structural complexity, diversity and novelty have emerged. These new formats exceed the capabilities and agility of existing biologics host cell lines and manufacturing methods. Limitations include low volumetric productivities due to cell propagation in fed-batch bioreactors, the time required to develop unique processes and cell lines for each new therapeutic, insufficient flexibility and control over post-translational modifications including disulfide bonds and glycosylation, and difficulties in producing and secreting new-to-biotech or even new-to-nature protein folds and structures due to balancing cellular viability and therapeutic production.

In this presentation, Weston Kightlinger, PhD, discusses how Resilience’s next generation biomanufacturing capabilities overcome these key bottlenecks and highlight its cell free protein synthesis platform. Resilience’s platform provides direct control over the protein synthesis environment in an in vitro coupled transcription-translation reaction that generates high titers of complex proteins from a DNA template in less than a day. He also describes how Resilience is leveraging the flexibility of its cell-free technology as well as process development and manufacturing infrastructure to unlock the potential of protein therapeutics that are difficult or impossible to manufacture by other means. Taken together, these advancements in the science of biopharmaceutical manufacturing and development free our partners to focus on the discoveries that improve patients’ lives.